The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years ...

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...

Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...